Elevance Health 8-K
Guidance reaffirmed
Officers expect to reaffirm FY2026 earnings and benefit expense ratio outlook in investor meetings; adjusted EPS excludes net unfavorable items.
Filed 2026-09-10 06:00 ET
- 7.01 Regulation FD Disclosure
Summary
Full-year 2026 guidance reaffirmation. Elevance officers expect to reaffirm the company’s earnings and benefit expense ratio outlook in investor meetings over the next several weeks. The earnings outlook includes ≈$6.90 per diluted share of net unfavorable items; adjusted earnings guidance excludes those items and no other adjustments beyond those reported in Q2 2026.
Guidance
| Metric | Period | Guidance | Prior | Direction |
|---|---|---|---|---|
| Shareholders’ earnings, per diluted share (GAAP) | FY2026 | At least $20.10 | — | Reaffirmed |
| Net unfavorable items, per diluted share | FY2026 | ≈$6.90 | — | Reaffirmed |
| Adjusted shareholders’ earnings, per diluted share (non-GAAP) | FY2026 | At least $27.00 | — | Reaffirmed |
| Benefit expense ratio | FY2026 | 90.2% ±50 bp | — | Reaffirmed |
Investor Takeaways
- FY2026 results versus the reaffirmed earnings thresholds and benefit expense ratio range will show whether the outlook holds.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3